Exeltis Faces Regulatory Cliff on Tafoxiparin Deal as Approval Failure Looms
Exeltis's semi-global license for tafoxiparin from Dilafor could become worthless if the drug fails regulatory approval in key markets. The women's health company faces medium-probability, catastrophic-severity risks that would void commercial value of the agreement. Market watchers rate the approval failure scenario at 70% confidence.
ViaNews Editorial Team (Markets)•